Carbon C 11 Acetate
Phase 1Biologic
Carbon C 11 Acetate is one of 52 biologic programs targeting Liver Cancer. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
61 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Blenoxane
Bristol-Myers SquibbApproved
Taxol
TevaApproved
Opdivo
Bristol-Myers SquibbPhase 3
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Eloxatin
TevaPhase 3
Lenvima
EisaiPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Bicnu
MMelissa K Accordino
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carbon C 11 Acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- MM.D. Anderson Cancer Center